Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences

[1]  S. Joel,et al.  Lack of pharmacokinetic interaction between 5‐fluorouracil and oxaliplatin , 2004, Clinical pharmacology and therapeutics.

[2]  E. Gamelin,et al.  Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Caen,et al.  Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  J. Robert,et al.  Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Hiddemann,et al.  Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Gamelin,et al.  A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites , 1997 .

[7]  E. Gamelin,et al.  Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[8]  J. Robert,et al.  Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[10]  F. Lévi,et al.  Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Gamelin,et al.  Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.

[12]  F. Demard,et al.  Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. , 1992, Cancer research.

[13]  A. Reinberg,et al.  A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer , 1992, Cancer.

[14]  J. Willson,et al.  Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Robert B. Diasio,et al.  Clinical Pharmacology of 5-Fluorouracil , 1989, Clinical pharmacokinetics.

[16]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Peters,et al.  Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. , 1988, Cancer research.

[18]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F N Naguib,et al.  Enzymes of uracil catabolism in normal and neoplastic human tissues. , 1985, Cancer research.

[20]  R. Dedrick,et al.  Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes , 1980, Clinical pharmacology and therapeutics.

[21]  J. Rosenfeld,et al.  Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. , 1978, British Journal of Cancer.

[22]  W. Wolberg,et al.  Pharmacokinetics of fluorouracil in humans. , 1978, Cancer research.

[23]  F. Demard,et al.  Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer , 2004, Cancer Chemotherapy and Pharmacology.

[24]  M. Ychou,et al.  Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  S. Iacobelli,et al.  Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. , 1993, European journal of cancer.

[26]  R. Diasio,et al.  Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. , 1990, Cancer research.

[27]  M. Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[28]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.